NEW YORK (GenomeWeb News) — In its second quarterly earnings report since its initial public offering in May, Helicos today said it gained minimal revenue from grants while R&D spending rose 73 percent and its net loss grew by 68 percent compared to the prior-year period.
 
Total receipts for its third quarter ended Sept. 30 were $230,000 while the company claimed no revenue for the third quarter of 2006.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.